Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Stonehands Jul. 6 at 9:56 PM

$BCTX

0 · Reply

TWBXX Jul. 6 at 8:46 PM

$BCTX The Immunomedics / ASCENT comparison is not hype — it’s structurally valid Your tab mentions: “Same population, same endpoint… Immunomedics got bought for $21B.” ASCENT also had an event‑driven OS endpoint. ASCENT also saw delayed events. ASCENT also produced a massive survival benefit. The pattern for BCTX you’re seeing now is the same pattern ASCENT showed before its readout. The trial is past its expected event‑maturity window. Events are accumulating slower than modeled. DSMB has repeatedly approved continuation. Phase 2 OS benefit was large. The design allows multiple paths to approval. All of that is consistent with a positive Phase 3 survival effect.

0 · Reply

BioRich Jul. 6 at 8:33 PM

$BCTX I can get behind this. Only a small position, but might have to change that. Been watching and looks like it's starting to move. Rotation out of $SLS appears to have begun. Still too much Tute/Short control to tip the cap, but $SLS appears "So June, 2026" at this point. Already seeing it roll into $DRTS, started to see it roll back into $IBRX and I wouldn't sleep on $TLSA at this point. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

BioRich Jul. 6 at 8:13 PM

$BCTX ready to pop?

0 · Reply

data_dave Jul. 6 at 6:41 PM

BCTX: Am I crazy or is the silence the most bullish signal possible? Event-driven Phase 3 in metastatic breast cancer. The trial ends at 144 deaths. Guided H1-2026, now delayed. In an event-driven trial, delayed events = patients living longer than modeled. DSMB greenlit 6x in a row, May 2026. No concerns. They would pull the plug if it wasn't working. Phase 2 showed 16.6 months median OS vs 7-11 months standard chemo. $27M market cap. FDA Fast Track. Nature Medicine "11 trials that will shape medicine in 2026". 70+ sites including Mayo Clinic, Cedars-Sinai, Penn/Abramson, Yale, Emory, Dartmouth. Last company that ran a similar play (Immunomedics/ASCENT, same population, same endpoint) got bought by Gilead for 21B, $88/share cash. Either I'm making a massive logical error or this is genuinely asymmetric. Tell me where I'm wrong. Full DD in images. Not financial advice. Long $BCTX. Binary bet, you can lose 100%. 💎🙌

4 · Reply

BHWinehouse Jul. 6 at 6:00 PM

$BCTX $BCTXL

0 · Reply

Manwiththeplan Jul. 6 at 5:58 PM

$BCTX no logic in selling now. Phase 3 data is coming.

0 · Reply

Manwiththeplan Jul. 6 at 5:45 PM

$BCTX

0 · Reply

Goodstockday Jul. 6 at 5:43 PM

$BCTX This is up big today, but with the current risk/reward situation it has plenty of room to keep climbing. It should be back to $4 soon and moving upward from there.

0 · Reply

Ares77manoe Jul. 6 at 5:42 PM

$BCTX. Please clowns show up...

0 · Reply

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-25T13:25:58.000Z - 11 days ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 11 days ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 11 days ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 4 weeks ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 5 weeks ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 5 weeks ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 6 weeks ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 6 weeks ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 7 weeks ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 7 weeks ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 7 weeks ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 2 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 2 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 2 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 2 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 2 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 3 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 3 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 3 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 4 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 4 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 4 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 4 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 4 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 5 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 5 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 5 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 6 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 6 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 6 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 6 months ago

Market Cap	28.36M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	357,523
Avg Vol	210,040
Day's Range	N/A - N/A
Shares Out	8.70M
Stochastic %K	59%
Beta	1.15
Analysts	Strong Buy
Price Target	$40.00